Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6023518 | 0.96 | KMT2A (0.55) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL6484083 | 0.90 | KMT2A (0.62) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL6478319 | 0.86 | KMT2A (0.62) | KMT2AGAA | |
| SCHEMBL6475948 | 0.84 | KMT2A (0.62) | KMT2AALDH1A1GAA | |
| SCHEMBL6023639 | 0.84 | — | — | |
| SCHEMBL6023129 | 0.83 | BCHE (0.54) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL3370380 | 0.82 | KMT2A (0.54) | KMT2AMEN1CA12CA1CA2 | |
| SCHEMBL6023108 | 0.81 | CA1 (0.54) | KMT2AMEN1CA1CA2ALDH1A1 | |
| SCHEMBL6022541 | 0.81 | CA1 (0.57) | KMT2AMEN1CA1CA2GAA | |
| SCHEMBL6476553 | 0.81 | KMT2A (0.55) | KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148838-A1 | Novel pyrrolodihydroisoquinolines useful in the treatment of cancer | ALTANA PHARMA AG (DE) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148838-A1 | Novel pyrrolodihydroisoquinolines useful in the treatment of cancer | MKI67, BAD, CCAR2 | KMT2A 1763/4885MEN1 3890/4885CA12 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.